Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

Nanoparticle may bring great benefits to emergency treatment of brain-injury victims

A nanoparticle developed at Rice University and tested in collaboration with Baylor College of Medicine (BCM) may bring great benefits to the emergency treatment of brain-injury victims, even those with mild injuries.

24 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

RNA-delivering nanoparticles allow rapid screening of new drug targets in mice

By sequencing cancer-cell genomes, scientists have discovered vast numbers of genes that are mutated, deleted or copied in cancer cells. This treasure trove is a boon for researchers seeking new drug targets, but it is nearly impossible to test them all in a timely fashion.

16 Aug 2012

Nanobiotix, PharmaEngine partner to develop NBTXR3 for cancer

French Nanobiotix S.A. announced today that it entered into a strategic partnership with PharmaEngine, Inc. for the rapid development of NBTXR3, the lead product from the NanoXray pipeline of Nanobiotix.

6 Aug 2012

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

PharmaEngine, Inc. announced today the execution of an exclusive license and collaboration agreement with France-based Nanobiotix S.A. for the development and commercialization of NBTXR3, currently being investigated in a phase I study with soft tissue sarcoma patients.

6 Aug 2012

LSDF announces $570,000 in awards to support commercialization of new health-related products

The Life Sciences Discovery Fund (LSDF) today announced nearly $570,000 in awards in its inaugural corporate grant program to support commercialization of new health and health-care products by four early-stage Washington-based companies.

25 Jul 2012

Nottingham scientists win £1.2M grant for research into engineering of nanomaterials

Pioneering scientists at The University of Nottingham have won a £1.2 million grant for research into the engineering of nanomaterials that could transform the global healthcare industry.

20 Jul 2012

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis.

16 Jul 2012

Researchers settle controversy over the mechanism by which silver nanoparticles kill bacteria

Rice University researchers have settled a long-standing controversy over the mechanism by which silver nanoparticles, the most widely used nanomaterial in the world, kill bacteria.

12 Jul 2012

New approach integrates rational drug design with supramolecular nanochemistry in cancer treatment

Researchers at Brigham and Women's Hospital (BWH) are the first to report a new approach that integrates rational drug design with supramolecular nanochemistry in cancer treatment.

11 Jul 2012

Nanoparticles that can slip through mucus barriers shown to protect against herpes infections

Johns Hopkins researchers say they have demonstrated, for the first time in animals, that nanoparticles can slip through mucus to deliver drugs directly to tissue surfaces in need of protection. The researchers used these mucus-penetrating particles (MPPs) to protect against vaginal herpes infections in mice and the goal is to create similar MPPs to deliver drugs that protect humans against sexually transmitted diseases or even treat cancer.

26 Jun 2012

NIH awards Sirnaomics SBIR grant for developing STP705 siRNA wound healing product

Sirnaomics, Inc. announced today that the company has been awarded another NIH SBIR grant for developing its small interfering RNA (siRNA) therapeutic product STP705 to improve skin wound healing with minimized scar formation.

25 Jun 2012

Selenium reduces Staph populations in medical implants

Selenium is an inexpensive element that naturally belongs in the body. It is also known to combat bacteria. Still, it had not been tried as an antibiotic coating on a medical device material. In a new study, Brown University engineers report that when they used selenium nanoparticles to coat polycarbonate, the material of catheters and endotracheal tubes, the results were significant reductions in cultured populations of Staphylococcus aureus bacteria, sometimes by as much as 90 percent.

22 Jun 2012

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).

20 Jun 2012

Synthesis of silver nanoparticles from pomegranates

Food waste is a growing problem in many parts of the world, but discarded fruit peel, in the case of pomegranates, could be put to good use in the burgeoning field of nanotechnology according to research published in the International Journal of Nanoparticles.

20 Jun 2012

Researchers engineer nanoparticles that show great promise for MM

Researchers from the University of Notre Dame have engineered nanoparticles that show great promise for the treatment of multiple myeloma (MM), an incurable cancer of the plasma cells in bone marrow.

16 Jun 2012

Azaya announces final results from ATI-1123 Phase I study on cancers

Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.

14 Jun 2012

Effective ways of detecting onset of kidney disease

Research led by an Arizona State University biomedical engineer and physicist to find more effective ways of detecting the onset of kidney disease is getting support from the National Institutes of Health.

8 Jun 2012

New nanomedicine cancer treatments promise to reduce severity of side effects

A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the current edition of Chemical & Engineering News.

7 Jun 2012

Biochemiresistor can quickly detect small traces of contaminants in liquids

A whole new class of biosensor that can detect exceptionally small traces of contaminants in liquids in just 40 minutes has been developed by a UNSW-led team of researchers.

1 Jun 2012

Nanoparticle News and Research

Further Reading

Nanoparticle may bring great benefits to emergency treatment of brain-injury victims

New results describe development of DC cancer vaccine with enhanced immunogenic potential

RNA-delivering nanoparticles allow rapid screening of new drug targets in mice

Nanobiotix, PharmaEngine partner to develop NBTXR3 for cancer

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

LSDF announces $570,000 in awards to support commercialization of new health-related products

Nottingham scientists win £1.2M grant for research into engineering of nanomaterials

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Researchers settle controversy over the mechanism by which silver nanoparticles kill bacteria

New approach integrates rational drug design with supramolecular nanochemistry in cancer treatment

Nanoparticles that can slip through mucus barriers shown to protect against herpes infections

NIH awards Sirnaomics SBIR grant for developing STP705 siRNA wound healing product

Selenium reduces Staph populations in medical implants

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

Synthesis of silver nanoparticles from pomegranates

Researchers engineer nanoparticles that show great promise for MM

Azaya announces final results from ATI-1123 Phase I study on cancers

Effective ways of detecting onset of kidney disease

New nanomedicine cancer treatments promise to reduce severity of side effects

Biochemiresistor can quickly detect small traces of contaminants in liquids

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery